Construction spending (Dec.) ISM manufacturing (Jan.) Auto Sales (Jan.) Featured Earnings Palantir Technologies Inc.

Shares of newly public Metsera (MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Read more here.

-- AstraZeneca has shelved a plan to build a vaccine manufacturing plant in Speke, near Liverpool, valued at 450 million pounds ($558.7 million), after months of talks with British government ...

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

FDA approved Ryoncil ® as the first and only therapy for pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), ...

This was the ADR's second consecutive day of gains.

In a report released yesterday, Seamus Fernandez from Guggenheim reiterated a Buy rating on AstraZeneca (AZN – Research Report), with a price ...

The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC . Shareholders who purchased shares of AZN ...

UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of p11,500.00. The ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

The latest trading day saw Astrazeneca (AZN) settling at $70.25, representing a +0.95% change from its previous close.